Back to mobile site

BofA Securities Reiterates Buy Rating on Vaxcyte (PCVX)

June 21, 2024 5:33 AM EDT Send to a Friend
BofA Securities analyst Jason Gerberry reiterated a Buy rating and $101.00 price target on Vaxcyte (NASDAQ: PCVX).The analyst comments "Vaxcyte’s ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login